Answers are grounded in this paper and cite their sources.
Robert Bazell. New York (NY): Random House, 1998. 214 pp., illus. $25. ISBN 0-679-45702-X Last year's media frenzy about the potential benefit of antiangiogenesis agents touted as a cancer cure once again left Americans wondering, “What is taking so long”? More desperately, this question is asked by millions of patients and their family members as they face catastrophic cancer diagnoses. Robert Bazell, chief Science correspondent for NBC News, has studiously answered this question—at least about one drug, Herceptin, used for breast cancer. Instead of the cruel and irresponsible hype that often surrounds reporting on new cancer treatment, in HER-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer, Bazell carefully and thoughtfully chronicles the saga of Herceptin's development. Cancer drug development is a dense and difficult topic, even for those who know the field intimately. It is not a neat scientific algorithm with straight and clear solutions. Bazell's style immediately engages the reader in the remarkable complexity of discovering, investigating, and finally proving that Herceptin helps extend the lives of some breast cancer patients. This explanation is no easy task when the complexity involves corporate bottom-lines, intrigue, and indifference; savvy, impassioned, and determined breast cancer patient advocates; and the brilliance and petty jealousies of scientists. Bazell makes it clear from the beginning that Herceptin's story includes the realities of breast cancer patients and the activists who support them, without whom this drug would have landed in the proverbial dust bin of history. His descriptions of the trial participants reveal his uncanny insight into the pain, confusion, and sheer terror that patients with breast cancer display, always in search of the latest treatment that might give them precious time. This type of insight is usually limited to those who have actually experienced a diagnosis of cancer. These determined women eventually find their way into the Herceptin clinical trials, but often only due to their persistence or “dumb luck,” as one breast cancer patient describes how she learned about the Herceptin clinical trial. That dumb luck—more euphemistically known as serendipity in scientific circles—is a recurring theme throughout this book. The promise of Herceptin began in 1979 when pioneering cancer researcher Robert Weinberg identified the gene—now known as HER-2—which is involved in multiple cancer pathways. At the same time, Genentech, the company that eventually brought Herceptin to market, was a fledgling biotechnology firm in south San Francisco. Bazell describes how this new “can do” company believed it could “carry out research of the highest quality and then turn the results into new drugs with a swiftness that the staid pharmaceutical companies could not match.” That was 1977, 21 long years before Herceptin's eventual approval. So what took so long? Bazell walks the reader through each step and misstep in a way that builds the reader's curiosity. It took 5 years to get from Dr. Weinberg's 1979 discovery of the neu oncogene to the identification, by Genentech scientist Alex Ullrich, of the protein produced by that gene. Next, he needed to know what role this protein played in cancer's onset or progression. Then, another stroke of dumb luck occurred in 1986. Ullrich accidentally met Dennis Slamon in a Denver airport. Slamon, a practicing oncologist at UCLA's Jonsson Cancer Center, is a dogged and devoted cancer researcher. Throughout the next 2 years, Slamon and Ullrich pursued the hypothesis that HER-2 neu played a role in the growth of breast and ovarian cancers. By 1987, they published their results, which suggested that cancers overexpressing HER-2 are more likely to recur and spread more quickly. But could their work be reproduced and their conclusion be confirmed? More delays ensued as their colleagues failed to reproduce their experiment. These delays were dumb bad luck. Two long years later, Slamon and Ullrich proved that the failure to reproduce their work was due to the “use of contaminated chemicals, faulty techniques, and idiotic mistakes by the laboratories conducting the experiments.” By 1988, Slamon and Ullrich looked to Genentech for support to take their promising experiment to the next level of development. Support was not forthcoming. Genentech was no longer focused on cancer drug development. Their oncology staff had been disbanded following the unsuccessful interferon-alfa trials. Herceptin's development languished until more dumb luck occurred. In late 1989, the mother of a senior Genentech vice president was diagnosed with breast cancer. “Just like that, one man flipped the switch on HER-2” and convinced his colleagues that HER-2 was worth Genentech's investment. Again, and not for the last time, an unexpected player would rescue Herceptin. Bazell's descriptions of the wrangling within Genentech and among the “ thought leaders” in oncology are fascinating and also frightening. One wants to believe that this incessant fighting is in the name of good science. For my part, the scientists seemed to exhibit more selfishness and egotism than one would hope, especially in the development of drugs for life-threatening diseases. But perhaps, in this domain of life-threatening diseases, it is precisely this egotism that accounts for the fact that only the strong survive. Like a good reporter, Bazell leaves conclusions about this aspect of Herceptin's development to the reader. Bazell integrates the chapters on science with vivid play-by-play descriptions of the savvy tactics employed by the breast cancer activists, such as ACT-UP Golden Gate, the Marti Nelson Cancer Research Foundation, Breast Cancer Action, and the National Breast Cancer Coalition. Their tenacity resulted in speedier case subject recruitment to the pivotal trial and the establishment of the compassionate access program. Bazell declares the activists as “the heroes of this tale.” The title of Bazell's book is a poor choice. One wonders why the publisher would handicap the book with a title like HER-2 that has no meaning to most Americans. Bazell's work deserves a title that grabs the interests of a bookstore browser. We can only hope that word of mouth will overcome this handicap. This important book should be read by scientists, Wall Street financiers, cancer patients, and yes, even the average American who has not experienced cancer . . . yet. Bazell's unvarnished account of Herceptin's development discloses the issues every American should understand as they try to grapple with the question of what is taking so long.
No takes yet. Share an insight, caveat, or question.
Patty Delaney (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: